The UK is often referred to as the 'sick man of Europe'. And at first glance the description may seem merited. Just last ...

MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children.

The company released its six-month results from its Phase 3 INHALE-1 pediatric diabetes trial. Here’s what you need to know.

For adults with type 1 diabetes, a regimen of inhaled Technosphere insulin (TI) plus insulin degludec is noninferior t ...

Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression The INHALE-1 study is a 26-week, ...

Millions of diabetes patients have to take a painful insulin injection to keep sugar levels in control. Cipla is introducing ...

Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

MannKind and Cipla announce CDSCO approves Afrezza inhalation powder in India: Our Bureau, Mumbai Thursday, December 12, 2024, 17:30 Hrs [IST] MannKind Corporation, a company focu ...

Mumbai: Cipla Limited has announced that it has obtained regulatory approval from Central Drugs Standard Control Organisation ...

Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes ...